Target- |
MechanismSmall interfering RNA modulators |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
MechanismSmall interfering RNA modulators |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
MechanismSmall interfering RNA modulators |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate the Efficacy and Safety of Subcutaneously Administered BW-00112 in Patients With Mixed Dyslipidemia
A Phase 2 in Patients With Mixed Dyslipidemia
100 Clinical Results associated with Shanghai Argo Biopharmaceutical Technology, Limited.
0 Patents (Medical) associated with Shanghai Argo Biopharmaceutical Technology, Limited.
100 Deals associated with Shanghai Argo Biopharmaceutical Technology, Limited.
100 Translational Medicine associated with Shanghai Argo Biopharmaceutical Technology, Limited.